TME Pharma and aimed analytics: Revolutionizing Drug Discovery with AI

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in novel therapies for cancer treatment by targeting the tumor microenvironment (TME), has announced a strategic collaboration with aimed analytics, a cutting-edge medical data analytics company. This partnership aims to leverage artificial intelligence (AI) to accelerate drug discovery and optimization, further enhancing TME Pharma's capability profile for potential strategic partners.



The global AI in drug discovery market is projected to grow at a CAGR of 20% during the forecast period (2024-2035), reaching USD 13.44 billion by 2035. This growth is driven by the increasing demand for advanced therapeutic drugs, the need for faster and more efficient drug discovery processes, and the growing availability of healthcare data.

The collaboration between TME Pharma and aimed analytics will focus on integrating AI and deep learning-driven insights into TME Pharma's drug discovery capabilities. By combining their expertise in development of oligonucleotide drugs, cancer biology, and immune-oncology with aimed analytics' advanced deep-learning models for structural prediction and AI-based models for molecular structure prediction, the two companies aim to create new and improved drug candidates without the need for time and resource-intensive laboratory testing.

This approach is expected to accelerate timelines, reduce associated costs, and minimize the need for experimental infrastructure. The partnership also aims to enable TME Pharma to bring its existing drugs to the table for strategic partners and potentially discover new drugs more efficiently.

The AI in drug discovery market is experiencing an upward trajectory due to the growing demand for advanced therapeutic drugs for targeting a broad range of disease indications. The market is segmented by drug discovery steps, therapeutic area, and key geographies. The market size is estimated to grow from USD 1.76 billion in 2024 to USD 13.44 billion by 2035, representing a higher CAGR of 20% during the forecast period.



The AI in drug discovery market is segmented by component (software, service), technology (machine learning {deep, supervised}), application type (target identification, preclinical testing), therapeutic area, and end-use. The market is expected to grow at a CAGR of 29.6% from 2024 to 2032, driven by factors such as a surge in investment and funding from venture capital firms, pharmaceutical companies, and government agencies.

In conclusion, the collaboration between TME Pharma and aimed analytics is a significant step towards revolutionizing drug discovery by leveraging AI. This partnership aligns with TME Pharma's broader strategic vision and is part of the company's ongoing efforts to enhance its drug discovery capabilities and market position. By integrating AI into its drug discovery process, TME Pharma aims to accelerate timelines, reduce costs, and potentially discover new drugs more efficiently, ultimately contributing to the development of more effective treatments for patients in need.